Aduro BioTech Licenses GVAX Pancreas From BioSante Pharmaceuticals To Develop A Therapeutic Vaccine In Conjunction With CRS-207 For Pancreatic Cancer

Links shared publicly online about this topic.

  • 354
    total visits

Aduro BioTech Licenses GVAX Pancreas From BioSante Pharmaceuticals To Develop A Therapeutic Vaccine In Conjunction With CRS-207 For Pancreatic Cancer

medicalnewstoday.com —

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine (GVAX Pancreas) and GVAX Prostate Cancer Vaccine (GVAX Prostate) from BioSante Pharmaceuticals, Inc

View full resource at medicalnewstoday.com

Tags: Vaccination, Pancreatic Disease, Cancer, Pancreatic Cancer, Pharma, Biotech, Vaccine

  • Share

Most Recently Shared on April 19, 2011 at 2:05 pm By:

mnt_vaccines MNT Vaccines

Aduro BioTech Licenses GVAX Pancreas From BioSante Pharmaceuticals To Develop A Therapeutic Vaccine In Conjunction Wit... http://mnt.to/3TPs

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cancer News MNT Cancer News

MNT Pancreatic Can MNT Pancreatic Can

Advertisement